Table 4.
Distribution of drug resistance and VF genes among ESBL producers and non ESBLUPEC
| Numbers and percentages of the isolates andtheir respective traits | ||||
|---|---|---|---|---|
| Resistance traits | All isolates (n = 155); n(%) | Non ESBL producers (n = 90) n(%) | ESBL producers (n = 65) n(%) | p value |
| Piperacillin tazobactam | 7(5) | 4(4) | 3(5) | > 0.9999 |
| Ceftazidime | 96(62) | 36(40) | 60(92) | < 0.0001 |
| Cefotaxime | 101(65) | 40(44) | 61(94) | < 0.0001 |
| Ceftriaxone | 99(64) | 49(54) | 50(77) | 0.0040 |
| Ciprofloxacin | 95(61) | 45(50) | 50(77) | 0.000684 |
| Levofloxacin | 97(63) | 48(53) | 49(75) | 0.0051 |
| Amikacin | 7(5) | 4(4) | 3(5) | 0.9597 |
| Gentamicin | 47(30) | 30(33) | 17(26) | 0.3373 |
| Amoxicillin-clavulanic acid | 111(72) | 50(56) | 61(94) | < 0.0001 |
| Trimethoprim sulfonamides | 130(84) | 67(74) | 63(97) | 0.0002 |
| Nitrofurantoin | 9(6) | 6(7) | 3(5) | 0.5900 |
| Fosfomycin | 15(10) | 8(9) | 7(11) | 0.6960 |
| fimH | 155 (100) | 90 (100) | 65 (100) | > 0.9999 |
| papA | 20 (13) | 12 (13) | 8 (12) | 0.8509 |
| papC | 75 (48) | 42 (47) | 33 (51) | 0.6140 |
| papEF | 37 (24) | 18 (20) | 19 (29) | 0.1834 |
| papGI | 6 (4) | 3 (3) | 3 (5) | 0.6831 |
| papGII | 70 (45) | 33 (37) | 37 (57) | 0.0124 |
| papGIII | 6 (4) | 4 (4) | 2 (3) | 0.6632 |
| sfa/foc | 20 (13) | 11 (12) | 9 (14) | 0.7660 |
| Afa | 15 (10) | 7 (8) | 8 (12) | 0.3466 |
| bmaE | 2 (1) | 1 (1) | 1 (2) | 0.8246 |
| fyuA | 37 (24) | 20 (22) | 17 (26) | 0.5710 |
| iutA | 86 (55) | 45 (50) | 41 (63) | 0.1060 |
| feoB | 76 (49) | 40 (44) | 36 (55) | 0.1788 |
| kpsmtII | 40 (26) | 19 (21) | 21 (32) | 0.1160 |
| kpsmtIII | 4 (3) | 2 (2) | 2 (3) | 0.4729 |
| Usp | 22 (14) | 10 (9) | 12 (18) | 0.1957 |
| hlyA | 18 (12) | 7 (8) | 11 (17) | 0.0795 |
| cdtB | 11 (7) | 6 (7) | 5 (8) | 0.8062 |
Distribution of resistance and virulence traits among ESBL and non-ESBL producing uropathogenic E. coli (N = 155). The p values were calculated by comparing different traits among ESBL producer’s and non-ESBL producers